PA
MGNX icon

Parallel Advisors’s MacroGenics MGNX Stock Holding History

Parallel Advisors’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-21
Closed -$141 – 3474
2022
Q4 		$141 Buy
+21
New +$115 ﹤0.01% 3232
2020
Q1 		– Sell
-342
Closed -$4K – 2542
2019
Q4 		$4K Buy
+342
New +$3.39K ﹤0.01% 2033
2019
Q3 		– Sell
-76
Closed -$1K – 2453
2019
Q2 		$1K Buy
+76
New +$1.3K ﹤0.01% 2211
2019
Q1 		– Sell
-82
Closed -$1K – 2346
2018
Q4 		$1K Sell
82
-29
-26% -$486 ﹤0.01% 2022
2018
Q3 		$2K Hold
111
– – ﹤0.01% 2020
2018
Q2 		$2K Hold
111
– – ﹤0.01% 1862
2018
Q1 		$3K Hold
111
– – ﹤0.01% 1739
2017
Q4 		$2K Hold
111
– – ﹤0.01% 1863
2017
Q3 		$2K Buy
+111
New +$1.92K ﹤0.01% 1863

Other funds holding MGNX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Parallel Advisors's MGNX Position: Q1 2023 in Review

Parallel Advisors sold out of MacroGenics (MGNX) in Q1 2023, closing a stake of 21 shares — an estimated $141 sold.

Parallel Advisors first reported a position in MGNX in Q3 2017 and held it in 9 quarters. The position peaked at $4K in Q4 2019. 137 funds tracked by Wall St. Rank hold MGNX as of Q1 2023.

  • Parallel Advisors reported no remaining MacroGenics position as of Q1 2023 after selling out during the quarter.
  • Parallel Advisors sold 21 MacroGenics shares in Q1 2023, an estimated $141.
  • Parallel Advisors first reported a position in MacroGenics in Q3 2017 and held it in 9 quarters.
  • Parallel Advisors's MacroGenics position peaked at $4K in Q4 2019.
  • 137 funds tracked by Wall St. Rank held MacroGenics as of Q1 2023.

Based on Parallel Advisors's 13F filing for Q1 2023, filed 25 Apr 2023.